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Candida bloodstream infections (CBI) are one of themost common nosocomial infections
globally, and they account for a high mortality rate. The increasing global prevalence of
drug-resistant Candida strains has also been posing a challenge to clinicians. In this
study, we comprehensively evaluated the biofilm formation and production of hemolysin
and proteinase of 63 CBI isolates derived from a hospital setting in Hong Kong as well
as their antifungal susceptibility both in the presence and in the absence of human
serum, using standard methodology. Candida albicans was the predominant species
among the 63 CBI isolates collected, and non-albicans Candida species accounted for
approximately one third of the isolates (36.5%). Of them, Candida tropicalis was the
most common non-albicans Candida species. A high proportion (31.7%) of the CBI
isolates (40% of C. albicans isolates, 10% of C. tropicalis isolates, 11% of C. parapsilosis
isolates, and 100% of C. glabrata isolates) were found to be resistant to fluconazole.
One of the isolates (C. tropicalis) was resistant to amphotericin B. A rising prevalence of
drug-resistance CBI isolates in Hong Kong was observed with reference to a previous
study. Notably, all non-albicans Candida species, showed increased hemolytic activity
relative to C. albicans, whilst C. albicans, C. tropicalis, and C. parapsilosis exhibited
proteinase activities. Majority of the isolates were capable of forming mature biofilms.
Interestingly, the presence of serum distorted the yeast sensitivity to fluconazole, but
not amphotericin B. Taken together, our findings demonstrate that CBI isolates of
Candida have the potential to express to varying extent their virulence attributes (e.g.,
biofilm formation, hemolysin production, and proteinase activity) and these, together with
perturbations in their antifungal sensitivity in the presence of serum, may contribute to
treatment complication in candidemia. The effect of serum on antifungal activity warrants
further investigations, as it has direct clinical relevance to the treatment outcome in
subjects with candidemia.
Keywords: Candida, antifungal susceptibility, virulence factors, clinical isolates, plasma protein binding
Seneviratne et al. Virulence of Candida Bloodstream Isolates
INTRODUCTION
Candida is an opportunistic pathogen that can cause life-
threatening systemic and bloodstream infections in humans
(Calderone and Clancy, 2002). It is the fourth leading cause
of bloodstream infection in the United States, accounting for
approximately 9% of the total bloodstream infections, following
coagulase-negative Staphylococci, Staphylococcus aureus, and
Enterococcus species (Wisplinghoff et al., 2004). In recent reports,
Candida spp. remains the leading fungal cause of central line-
associated bloodstream infections (Hidron et al., 2008; Sievert
et al., 2013). Despite the advent of many new antifungal agents,
the incidence of Candida bloodstream infection (CBI) has been
steady over the past decades (Pfaller and Diekema, 2007). In
addition to its high incidence, the attributable mortality rate and
the associated cost burden are substantial (Wilson et al., 2002;
Warnock, 2007). In Hong Kong, an epidemiological study (Yap
et al., 2009) revealed a high prevalence, associated mortality, and
morbidity of CBI.
Of the Candida species, Candida albicans is by far the
predominant species of CBI (Pfaller et al., 2001, 2011; Labbé et al.,
2009). However, recently, the incidence of CBI caused by non-
albicans species (NAC) has increased and some of the common
species isolated are Candida tropicalis, C. parapsilosis, C. glabrata,
C. guilliermondii, C. dubliniensis, and C. krusei (Falagas et al.,
2010). The key virulence factors of Candida that are associated
with bloodstream infections include hemolysin production,
proteinases production and biofilm formation (Calderone and
Fonzi, 2001; Lim et al., 2012). Hydrolytic enzymes, such as
proteinases, of Candida species sequester nitrogen from proteins
of the host and facilitates tissue invasion (Staib, 1966; Schaller
et al., 2005), whereas, hemolysin is needed to acquire iron from
the hosts (Nayak et al., 2013). However, it should be noted that the
relevance of secreted aspartyl proteinases to the fungal virulence
is questionable as shown in data from animal studies (Correia
et al., 2010).
Biofilm formation is another feature that contributes to
Candida pathogenicity in catheter-related bloodstream infection
(Shin et al., 2002).Candida biofilm is known to be highly resistant
to antifungal agents, and it is thus a key attribute to the mortality
in bloodstream infections (Seneviratne et al., 2008a). In addition,
rising drug resistance among Candida species has posed a great
challenge to clinicians, especially when treating bloodstream
infections (Pfaller et al., 2011). Furthermore, there are only a few
studies in the literature that examine the antifungal susceptibility
and virulence attributes of CBI such as biofilm formation in Asian
populations (Shin et al., 2002; Seneviratne et al., 2011; Tay et al.,
2011; Kaur et al., 2014; Tellapragada et al., 2014).
In general, the pharmacologic effect of protein-bound drugs is
lower than their unbound counterparts. The protein binding of
a drug influences the amount of free unbound drug at the site of
infection, as well as its pharmacokinetics and pharmacodynamics
(Ashley et al., 2006). This is particularly important for drugs
targeting bloodstream infections where the drug is intrinsically
exposed to the serum proteins. However, studies on Candida
bloodstream isolates rarely attempted to capture the latter, real-
life scenario by evaluating the in vitro minimum inhibitory
concentration (MIC) of antifungals against these isolates in the
presence of serum.
In the present study, we comprehensively evaluated 63 isolates
from candidemic patients for their pathogenic attributes such
as hemolysin and proteinase production, and biofilm formation
as well as the susceptibility to the two most commonly used
antifungals, amphotericin B (a fungicidal agent) and fluconazole
(a fungistatic agent). Moreover, taking the foregoing research gap
into consideration, we also evaluated the MIC of these antifungal
agents in a serum-laced environment. Our study demonstrated
that CBI isolates are able to express pathogenic attributes to
varying extent; furthermore, the susceptibility of these isolates
against fluconazole is influenced in the presence of serum.
MATERIALS AND METHODS
Species Identification of Candida
Bloodstream Infection Isolates
Anonymous archival collection of Candida isolates was used in
the study with the approval of exemption from the Institutional
Review Board of the University of Hong Kong/Hospital
Authority Hong Kong West Cluster (HKU/HA HKW IRB). It
has been accepted by the funding authority, the Research Office
of the Food and Health Bureau, the Government of the Hong
Kong Special Administrative Region (Health &Medical Research
Fund, Project no.: 12111512). This study included 63 CBI isolates
derived from two hospitals i.e., QueenMaryHospital (23 isolates)
and Queen Elizabeth Hospital (40 isolates) in Hong Kong. The
Candida strains were isolated from patients before any antifungal
medication was administered. Species identification of Candida
isolates was performed by two standard culture-dependent
methods, namely CHROMagar (CHROMagar™ Candida) and
commercially available identification kit API 32C AUX method
(bioMérieux SA, France; Odds and Bernaerts, 1994). In brief,
CHROMagar differentiates various species of Candida by
formation of specific colored colonies when incubated at 37◦C
for 48–72 h. API 32C AUX assay is a carbohydrate assimilation
test which identifies the species based on their sugar metabolism.
Antifungal Susceptibility Testing
Antifungal susceptibility testing of the CBI isolates in planktonic
mode was performed using Clinical Laboratory Standards
Institute method (CLSI) protocol M27-A3 (broth microdilution
assay; Seneviratne et al., 2008b; Fothergill, 2012). Two-fold
dilution series of amphotericin B and fluconazole was prepared
in RPMI 1640 medium. For the serum induction experiment,
RPMI 1640 supplemented with 50% (v/v) human serum (Sigma)
was used (Wiederhold et al., 2007). Inocula from 24 h Candida
cultures were harvested and suspended in RPMI with turbidity
equivalent to McFarland standard 0.5 (1× 106 cells/ml) and then
diluted to approximately 0.5 × 103–2.5 × 103 cells/ml. The test
was performed in pre-sterilized, flat-bottom 96-well polystrene
plates (Iwaki, Japan). C. albicansATCC 90028 was used as quality
control strain. Plates were incubated at 37◦C for 48 h. MIC was
defined as the lowest concentration of the drug that completely
inhibits the growth according to the CLSI criteria.
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Hemolysin Assay
Hemolysin assay for Candida strains was performed according to
a previously validated protocol by our group (Luo et al., 2001).
In brief, Sabouraud dextrose agar supplemented with 7% sheep
blood and 3% glucose was used to determine the hemolysin
production by the CBI isolates. Suspension of yeast (1 × 108
cells/ml) was prepared in phosphate buffered saline (PBS; pH 7.2,
0.1 M) and 10µl was spot-inoculated on sheep blood agar plates,
incubated at 37◦C in 5% CO2 for 48 h. The diameters of the
colony and the transparent halo were measured by computerized
image analyzer (Qwin, Leica, UK). The hemolysin index (Hi)
was calculated by dividing the diameters of the colony and the
transparent halo. The assay was performed on two separate
occasions as quadruplicates for all isolates.
Proteinase Assay
The activity of secreted aspartyl proteinases was determined
by the bovine serum albumin (BSA) plate assay with some
modifications to the previous methods (Staib, 1966; Wu et al.,
1996). Suspensions equivalent to 0.5McFarland standard (1×106
cells/ml) were prepared from 18-h yeast cultured in Sabouraud
dextrose agar (SDA) and 10µl was spotted on 1% BSA plates.
The plates were incubated at 37◦C for 120 h. C. albicans ATCC
90028 and C. parapsilosis ATCC 22019 were used as positive and
negative controls. The plates were stained with staining solution
containing 1.25% of naphthalene black in 90% methanol/water
(v/v) for 5min and decolorized in 90% methanol/water (v/v)
for 48 h. The diameters of the colony and the transparent halo
were measured using the computerized image analyzer (Qwin,
Leica, UK). Proteinase production index (Ppr) was calculated by
dividing the diameters of the transparent halo and the colony
by the diameter of the colony. The assay was performed on two
separate occasions as quadruplicates for all isolates.
Biofilm Formation and XTT Reduction
Assay
Biofilm formation of CBI isolates was analyzed by previously
validated method by our group (Seneviratne et al., 2008b).
In brief, a loopful of 18 h culture grown at 37◦C in SDA
was harvested and suspended overnight in yeast nitrogen
base medium (YNB) supplemented with 50mM glucose in a
rotary shaker at 80 rpm overnight at 37◦C. Yeast cells in the
late exponential phase of growth were extracted and washed
twice with PBS. Then, the cells were re-suspended in YNB
supplemented with 100mM glucose with turbidity equivalent
to 4 McFarland standard. C. albicans ATCC 90028 was used
as a control for comparison. Hundred microliters of the yeast
suspension was transferred to the 96-well polystrene plate and
incubated at 37◦C for 90min (adhesion phase) in an orbital
shaker rotating at 80 rpm. Then, the medium was aspirated
and the biofilms were washed twice with 100µl of PBS to
remove unattached cells. After washing, 200µl of YNB medium
with 100mM glucose was added to each well. The plates were
incubated at 37◦C in a rotary shaker at 80 rpm for 48 h, with a
change of the growth medium at 24 h. After the 48 h incubation
period, the growth medium was pipetted out and the biofilms
were washed twice with 200µl of PBS before quantifying with
XTT reduction assay (Ramage et al., 2001). In brief, 200µl
of the XTT solution was added to the wells and the plate
was incubated in the dark at 37◦C for 3 h. The XTT solution
consisted of 40µl of XTT stock solution (1mg/ml in PBS) and
2µl of menadione (0.4mM in acetone) topped up to 200µl
in PBS. After incubation, 100µl of the colored solution was
aspirated from all the wells, transferred to Eppendorf tubes and
centrifuged at 8000 rpm for 10min. The centrifuged solution
was transferred to a different microtitre plate and the optical
density (OD) of the change in color was measured using a plate
reader (SpectraMAX 340 Tunable Microplate Reader; Molecular
Devices Ltd., Sunnyvale, CA) at 490 nm. This test was performed
in duplicates.
Genotyping of the Candida Isolates by
Random Amplification of Polymorphic DNA
(RAPD)
The genetic similarities of the C. albicans and C. tropicalis isolates
were examined by DNA fingerprinting through RAPD analysis.
Genomic DNA of the isolates was extracted using the QIAamp
DNA Mini Kit (Qiagen, Germany) according to the instructions
of the manufacturer. The PCR master mix was prepared with
2µL (100 ng/µL) of genomic DNA, 5µL 10X PCR buffer
(200mMTris/HCl, pH 8.4, 500mMKCl), 200µMdNTPs, 25mM
MgCl2, 1µM primer (T3B, 5′-AGG TCG CGG GTT CGA ATC
C-3′; Thanos et al., 1996) and 1.5U Taq Polymerase (Invitrogen).
PCR was performed by a thermal cycler (GeneAmp PCR System
9700, Applied Biosystems), with the first five cycles at 94◦C
for 5min, followed by 35 cycles of denaturation (94◦C, 30 s),
annealing (52◦C, 2min) and elongation (72◦C, 2min), and lastly,
final elongation at 72◦C for 10min. Positive control (genomic
DNA of C. albicans SC5314) and negative control (water) were
added in each PCR run. Gel electrophoresis of the PCR products
was performed in 1% agarose gel at constant voltage of 150V
for approximately 1 h. The bands were visualized by UV light
(ChemiDoc Imaging System, Bio-Rad, USA) after staining with
ethidium bromide. The bands of the isolates were analyzed
and dendrogram was constructed by the unweighted pair group
method in the program GelJ (Heras et al., 2015).
Statistical Analysis
One-way ANOVA with Bonferroni’s corrections were used for
multiple comparisons of hemolysin index, proteinase production
index and optical densities of the XTT reduction assay in Prism
6 (GraphPad Software, La Jolla, CA). A p-value of 0.05 or lower
was considered to be significant.
RESULTS
Species Distribution of the Isolates
Of the 63 Candida bloodstream isolates included in the study,
C. albicans was the most commonly detected species (n = 40),
followed by C. tropicalis (n = 10), C. parapsilosis (n = 9),
C. glabrata (n = 2), C. guilliermondii (n = 1) and C. dubliniensis
(n = 1; Table 1).
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Antifungal Susceptibility Testing
The planktonic cells of all the isolates were susceptible to
amphotericin B, except for a single isolate of C. tropicalis
exhibiting marginal resistance with 2µg/ml as MIC (Table 2).
A total of 31.7% of the CBI isolates was resistant to fluconazole
(MIC > 32µg/ml). Of the C. albicans isolates, 16 (40%) were
resistant to fluconazole. For the NAC, all the C. glabrata isolates
were resistant to fluconazole, whilst all the C. guilliermondii and
C. dubliniensis were susceptible. However, it has to be aware that
the low number of isolates of these three species may not be
representative.
Interestingly, serum-laced AST media did not alter the
activity of amphotericin B. On the other hand, 9 out of 63
isolates showed an increase in MIC of fluconazole in serum-
laced media (Table 3). Seven isolates exhibited four-fold raise
in MIC (S18, S25, M4, M5, M6, M8, and M16) and two
isolates exhibited three-fold increase (S29 and S14). On the
contrary, a few isolates (S15, S17, S36, and S11) showed
three-fold reduction in the MIC in the serum-laced medium
(Table 4).
Hemolysin Activity
The mean hemolysin index of the C. albicans isolates was
the lowest among all the species tested (1.592 ± 0.129).
It was significantly lower than the mean hemolysin index
of C. tropicalis and C. glabrata. Only two out of nine
C. parapsilosis isolates produced hemolysin on the blood agar,
TABLE 1 | Species distribution of the Candida bloodstream infection
isolates.
Species No. of isolates (%)
C. albicans 40 (63.5)
C. tropicalis 10 (15.9)
C. parapsilosis 9 (14.3)
C. glabrata 2 (3.2)
C. guilliermondii 1 (1.6)
C. dubliniensis 1 (1.6)
Total 63 (100)
while all isolates of other species exhibited hemolytic activity
(Table 5).
Proteinase Activity
No proteinase activity was observed in the C. glabrata,
C. guilliermondii, and C. dubliniensis isolates (Table 5).
Proteinase activity was observed among the remaining species
(C. albicans, C. tropicalis, and C. parapsilosis) and no statistical
significant difference was observed between the mean proteinase
indices of these three species.
Biofilm Formation and XTT Assay
C. albicans formed significantly more robust biofilms when
compared to NAC (Figure 1). Of the two C. glabrata isolates, one
produced very minimal biofilm, which gave the optical density
(OD) of 0.138 as examined by XTT reduction assay and was
10 times less than the average optical density of the C. albicans
biofilm (OD = 1.087). C. guilliermondii and C. dubliniensis
produced moderate biofilms (OD= 0.9).
TABLE 3 | Fluconazole susceptibility of Candida bloodstream isolates that
showed increase in MIC under 50% serum induction.
Isolates MIC (µg/ml)
RPMI RPMI + 50% serum
C. albicansa
S18 8 128
S25 8 128
S29 16 128
M4 4 64
M5 2 32
M6 2 32
M8 8 128
C. tropicalisb
S14 8 64
M16 8 128
MIC, minimum inhibitory concentration.
a17.5% (7 out of 40) of C. albicans isolates.
b20% (2 out of 10) of C. tropicalis isolates.
TABLE 2 | Antifungal susceptibility of Candida bloodstream isolates.
Species No. of isolates Amphotericin B Fluconazole
Susceptible Resistant Susceptible Resistant
MIC < 2µg/ml MIC ≥ 2µg/ml MIC ≤ 32µg/ml MIC > 32µg/ml
C. albicans 40 40 (100%) 0 (0%) 24 (60%) 16 (40%)
C. tropicalis 10 9 (90%) 1 (10%) 9 (90%) 1 (10%)
C. parapsilosis 9 9 (100%) 0 (0%) 8 (88.9%) 1 (11.1%)
C. glabrata 2 2 (100%) 0 (0%) 0 (0%) 2 (100%)
C. guilliermondii 1 1 (100%) 0 (0%) 1 (100%) 0 (0%)
C. dubliniensis 1 1 (100%) 0 (0%) 1 (100%) 0 (0%)
Total 63 62 (98.4%) 1 (1.6%) 43 (68.3%) 20 (31.7%)
MIC, minimum inhibitory concentration.
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Genotyping of the Candida Isolates by
(RAPD)
Genotyping was performed for C. albicans and C. tropicalis
strains. It seemed that strains derived from QueenMary Hospital
(23 isolates) and Queen Elizabeth Hospital (40 isolates) are
genetically quite similar (Supplementary Figures 1, 2). There was
no clear genotype specially associated with a particular hospital.
There was also no clear association between the genotype of
the species with their phenotypic features of biofilm formation,
hemolysin index and proteinase index.
DISCUSSION
Candidemia due to NAC has shown a steep rise in recent decades
(Samonis et al., 2008; Rodríguez et al., 2010). In the present study,
NAC accounted for a high proportion of all the CBI isolates
collected (36.5%), of which C. tropicalis was the most common.
These results reaffirm the findings of ours (Seneviratne et al.,
2011) and a 9-year long study conducted by Yap et al. (2009),
where NAC accounted for 46% of the 128 CBI isolates collected
in Hong Kong, with C. tropicalis being the most common NAC.
Similarly, C. tropicalis is also the most common NAC amongst
TABLE 4 | Fluconazole susceptibility of Candida blood isolates that
showed decrease in MIC under 50% serum induction.
Isolates MIC (µg/ml)
RPMI RPMI + 50% serum
C. albicansa
S15 16 2
S17 32 4
C. glabratab
S36 32 4
C. tropicalisc
S11 32 4
MIC, minimum inhibitory concentration.
a5% (2 out of 40) of C. albicans isolates.
b50% (1 out of 2) of C. glabrata isolates.
c10% (1 out of 10) of C. tropicalis isolates.
the Candida bloodstream isolates collected in other regions of
Asia (Chen et al., 1997, 2011; Jung et al., 2012; Chander et al.,
2013; Kaur et al., 2014). These data are in contrast to those from
Europe and the Northern and Latin America, where C. glabrata
and C. parapsilosis were the most common NAC in bloodstream
isolate (Pfaller et al., 2011). Clinicians should be mindful of the
geographical variation in the prevalence of different NAC species,
as they are often associated with higher mortality and resistance
to antifungals (Pfaller et al., 2011; Silva et al., 2012).
The increased prevalence of fungal infections and the
concomitant prescription of antifungals, have led to emergence
of drug-resistant Candida strains in the communities worldwide
(Arendrup et al., 2013). For instance, fluconazole-resistance is
now widespread owing to increased use of antifungals (Anaissie
FIGURE 1 | Biofilm formation of the Candida bloodstream infection
isolates measured by XTT reduction assay. OD, optical density; Ca,
C. albicans; Ct, C. tropicalis; Cp, C. parapsilosis; Cg, C. glabrata; Cgui,
C. guillermondii; Cd, C. dubliniensis; Control, C. albicans ATCC 90028; Error
bars, standard deviation; # Standard deviations could not be determined due
to the low number of isolates, *p < 0.05. The biofilm of each Candida
bloodstream infection isolate was quantified by XTT reduction assay. The
readings of isolates of each Candida species were averaged. Among all the
Candida species tested, C. albicans biofilm was the most robust, whilst
C. glabrata biofilm was the least robust. C. albicans biofilm was significantly
more robust than those of C. tropicalis and C. parapsilosis. No significant
difference was observed between the biofilm of C. tropicalis and
C. parapsilosis. The optical density of each of the individual isolates is provided
in Supplementary Table 1.
TABLE 5 | Hemolysin index and proteinase index of the Candida bloodstream infection isolates.
Species (n) Hemolysin index
mean ± SD
No. of hemolysin-positive
isolate/total no. of isolates
Proteinase index
mean ± SD
No. of proteinase-positive
isolate/total no. of isolates
C. albicans (40) 1.592 ± 0.129 40/40 1.854 ± 0.262 31/40
C. tropicalis (10) 1.949 ± 0.206a 10/10 1.799 ± 0.130 8/10
C. parapsilosis (9) 1.778 ± 0.230 2/9 1.640 ± 0.101 6/9
C. glabrata (2) 2.058 ± 0.078a 2/2 1 0/1
C. guilliermondii (1) 1.727 1/1 1 0/1
C. dubliniensis (1) 2.074 1/1 1 0/1
n, number of isolates; SD, standard deviation; a, significant higher than C. albicans. The hemolysin index was calculated by dividing the diameter of the transparent hemolytic halo with
that of the fungal colony. Similarly, the proteinase index was determined by dividing the diameter of the transparent proteolytic halo with that of the fungal colony. A value of one indicates
the absence of enzyme activity, and is excluded in the calculation of the mean. The hemolysin and proteinase indices of each of the individual isolates are provided in Supplementary
Table 1.
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et al., 1996; Kanafani and Perfect, 2008). In a previous study
we reported that all of the Hong Kong derived CBI isolates
(including C. tropicalis) were susceptible to amphotericin B and
fluconazole (Seneviratne et al., 2011). In contrast, in the present
study, almost a third (31.7%) of the CBI isolates were resistant
to fluconazole. Indeed, a single isolate of C. tropicalis showed
marginal resistance (2µg/ml) to amphotericin B (Table 2).
Resistance to amphotericin B has been recorded rarely in the past,
especially in C. tropicalis (Drutz and Lehrer, 1978). These data
point toward a rather insidious emergence of drug-resistance in
CBI in Hong Kong, and hence, the need for constant vigilance
accompanied by clinical surveillance studies.
Protein binding plays an important role in determining the
pharmacodynamics of a drug. Various studies have shown that
serum alters the MIC of antifungal drugs (Zhanel et al., 2001;
Bekersky et al., 2002). Higher dose is required for highly protein-
bound drugs to exhibit the samemicrobial killing efficiency when
compared to low protein-bound drugs (“free drug hypothesis”;
Drusano, 2004). Amphotericin B is a highly protein-bound drug
(>95%) and it is anticipated that there would be an increase in
MICs for Candida in vitro in the presence of serum proteins,
while the MICs of fluconazole, which is a weakly-bound drug
(11%), may remain unchanged (Humphrey et al., 1985; Bekersky
et al., 2002; Ashley et al., 2006).
Other studies have shown that half maximal effective
concentration (EC50) of amphotericin B significantly increased
for C. albicans ATCC 90028 and C. lusitaniae in RPMI
supplemented with 4 and 8% human serum albumin (Lewis et al.,
2006). In contrast, some studies exhibited results contradictory
to the free drug hypothesis (Zhanel et al., 2001; Zeitlinger et al.,
2011; Elefanti et al., 2013). In the study by Zhanel et al. (2001),
the MICs of amphotericin B of all the 10 isolates examined were
not altered in RPMI with 80% fresh human serum; whereas, 64%
of the isolates tested displayed increase in MIC of fluconazole
in RPMI with 80% human serum, and the remaining isolates
showed no change inMIC. In our study, all the isolated examined
displayed no change in the MICs to amphotericin B in the
presence of serum proteins. As for fluconazole, the MICs of the
majority of the isolates remained unchanged, but 14.3 and 6.3%
of the 63 isolates exhibited an increased and decreased MICs,
respectively in the presence of serum proteins (Tables 3, 4). Our
data, therefore, confirm the notion that the in vitro efficacy of
an antifungal drug does not necessarily depend upon its protein
binding capacity as suggested by others (Zhanel et al., 2001;
Elefanti et al., 2013).
Hemolysin is produced by some species of Candida which
destroy the circulating erythrocytes to acquire elemental iron
from hemoglobin (Schaible and Kaufmann, 2004). In the present
cohort, all the CBI isolates, except C. parapsilosis, exhibited
hemolytic activity (Table 5). Interestingly, the hemolytic-positive
isolates of NAC species exhibited higher hemolytic activities than
C. albicans. This is in contrast to the studies of Luo et al. (2001)
who reported that C. albicans as the most potent hemolytic
species.
Secreted aspartyl proteinases of Candida are thought to
degrade human proteins and provide nitrogen for the fungal
growth (Naglik et al., 2003). Only C. albicans, C. tropicalis, and
C. parapsilosis) in the present cohort demonstrated proteolytic
activities, whilst C. glabrata, C. guilliermondii, and C. dubliniensis
were devoid of such activity (Table 5).
Candida spp. are known to form highly organized biofilms,
especially on indwelling catheters and other prosthetic devices
(Seneviratne et al., 2008a). Different Candida species are also
known to have both inter- and intra-species variations in biofilm
development (Seneviratne et al., 2008a; Silva et al., 2010). In the
present study, all the CBI isolates, except C. glabrata, were good
biofilm formers, with C. albicans being superior to other species,
followed by C. tropicalis and C. parapsilosis (Figure 1). It has
been found that the mortality of CBI caused by biofilm-forming
Candida spp. are higher than those caused by non-biofilm-
forming counterparts (Tumbarello et al., 2012). Moreover, non-
albicans Candida species isolated from bloodstream were found
to be higher biofilm formers than those isolated from other
sites (Shin et al., 2002). Patients treated with anti-biofilm
antifungal agent (caspofungin), which demonstrates anti-biofilm
efficacy in vitro, were more commonly associated with shorter
post-CBI hospitalization than those treated with non-anti-
biofilm antifungal agent (fluconazole; Tumbarello et al., 2012).
Furthermore, the lower antifungal susceptibility associated with
Candida biofilm is often implicated in treatment complication
(Douglas, 2003; Seneviratne et al., 2008a). Our current finding
adds to the evidence that biofilm formation is a major
virulence factor that may lead to treatment complication of
CBI. Genotyping of the C. albicans and C. tropicalis strains
using RAPD showed that the strains derived from Queen Mary
and Queen Elizabeth hospitals in Hong Kong are quite similar.
There was no clear pattern of genotypic and phenotypic features
of the Candida strains. This is possibly due to genetic and
environmental relatedness of the strains in a single country.
Other studies have shown geographical location is a major factor
associated with genetic relatedness (Dassanayake et al., 2006).
Therefore, future studies should aim to compare genotype of the
Candida isolates with other regional countries.
In conclusion, the present study demonstrates that CBI
isolates are to varying extents capable of expressing virulence
attributes such as biofilm formation, hemolysin production and
proteinase activity. C. albicans is the predominant pathogenic
species in Hong Kong patients, while the proportion of NAC
species remains high. Our current findings further demonstrate
that C. tropicalis is the most common NAC isolated from CBI
in Asia. Almost all the isolates we have evaluated are able to
form mature biofilms. Antifungal resistance among CBI isolates,
particularly for fluconazole is variably demonstrated amongst the
isolates, a critical factor that should be borne in mind when
managing candidaemic patients for effective care. Finally, this
study indicates that the presence of serum may perturb the
activity of some antifungal agents, a factor that needs to be
considered when prescribing antifungals in candidemias.
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